Work

74P Predicting the risk of immunotherapy-induced versus other-cause pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors

Year: 2021

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.10.092

Authors: F. Tohidinezhad, L. Hendriks, A-M.C. Dingemans, J.G. Aerts, G. Bootsma, J.F. Vansteenkiste, S. Hashemi, E.F. Smit, H. Gietema, H.J. Aerts, A. Dekker, A. Traverso, D. De Ruysscher

Institutions: Maastricht University Medical Centre, Maastricht University, Erasmus MC, Zuyderland Medisch Centrum, Universitair Ziekenhuis Leuven, Amsterdam University Medical Centers, Amsterdam UMC Location Vrije Universiteit Amsterdam, The Netherlands Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4200141621

FWCI:

Cites:

Cited by:

Related to: 10